Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Maximize Your Synapse Use: Your Guide to Searching Clindamycin
Drug Insights
2 min read
Maximize Your Synapse Use: Your Guide to Searching Clindamycin
6 February 2024
Clindamycin was first made in 1966 from lincomycin and it is of the lincosamide class and works by blocking bacteria from making protein.
Read →
Alligator Bioscience Shows Promising Phase 2 Results from OPTIMIZE-1 Study Against Pancreatic Cancer
Latest Hotspot
3 min read
Alligator Bioscience Shows Promising Phase 2 Results from OPTIMIZE-1 Study Against Pancreatic Cancer
4 February 2024
Alligator Bioscience Reveals Encouraging Phase 2 Outcomes from OPTIMIZE-1 Study, Succeeding in Main Goal and Showing Significant Survival Advantages for Initial Treatment of Pancreatic Cancer.
Read →
Master Levothyroxine Search on Synapse
Drug Insights
2 min read
Master Levothyroxine Search on Synapse
4 February 2024
Levothyroxine Sodium is a small molecule drug that mimics and targets the thyroid hormone as an agonist.
Read →
Vidac Pharma Shares Promising Early Phase 2a Trial Results for Rare Skin Cancer Drug, VDA-1102
Latest Hotspot
3 min read
Vidac Pharma Shares Promising Early Phase 2a Trial Results for Rare Skin Cancer Drug, VDA-1102
4 February 2024
Vidac Pharma shares encouraging early results from a Phase 2a trial for a rare skin cancer, cutaneous T-cell lymphoma, using its primary drug candidate, VDA-1102.
Read →
Unveiling Azithromycin: How to Search for it on Synapse
Drug Insights
2 min read
Unveiling Azithromycin: How to Search for it on Synapse
4 February 2024
Azithromycin, a small molecule drug, works by targeting the 50S subunit of the bacterial ribosome and disrupting protein synthesis, ultimately leading to bacterial death.
Read →
Asieris Presents Early Results of APL-1202 and Tislelizumab Study for Advanced Bladder Tumors at ASCO-GU 2024
Latest Hotspot
3 min read
Asieris Presents Early Results of APL-1202 and Tislelizumab Study for Advanced Bladder Tumors at ASCO-GU 2024
4 February 2024
Asieris Debuts Preliminary Results from Study on APL-1202 Pill Paired with Immune Checkpoint Blocker Tislelizumab for Pre-Surgical Care in Advanced Urinary Bladder Tumors at ASCO-GU 2024 Event.
Read →
Expert Tips for Searching Amitriptyline on Synapse
Drug Insights
2 min read
Expert Tips for Searching Amitriptyline on Synapse
4 February 2024
Amitriptyline Hydrochloride, a small molecule drug, is a reuptake inhibitor targets the monoamine transporters.
Read →
Celltrion USA Finalizes Application for Biosimilar Approval, Targets CT-P47 (ACTEMRA® Counterpart)
Latest Hotspot
3 min read
Celltrion USA Finalizes Application for Biosimilar Approval, Targets CT-P47 (ACTEMRA® Counterpart)
4 February 2024
Celltrion USA has finalized its application for a biosimilar approval, targeting CT-P47, a counterpart to the drug ACTEMRA® (tocilizumab).
Read →
Navigating Health Information: How to Use Synapse to Search for Diclofenac
Drug Insights
2 min read
Navigating Health Information: How to Use Synapse to Search for Diclofenac
4 February 2024
Diclofenac Sodium, a minuscule molecule drug, wields its prowess by targeting the COX enzyme as an inhibitor.
Read →
EU Commission Approves Takeda's HYQVIA® for Chronic Inflammatory Demyelinating Polyneuropathy Treatment
Latest Hotspot
3 min read
EU Commission Approves Takeda's HYQVIA® for Chronic Inflammatory Demyelinating Polyneuropathy Treatment
4 February 2024
European Commission Sanctions Takeda's HYQVIA® for Ongoing Treatment in Chronic Inflammatory Demyelinating Polyneuropathy Cases.
Read →
Unveiling the Updated Email Alert Feature in Synapse Database: A Game-changer in Data Management
Feature Updates
6 min read
Unveiling the Updated Email Alert Feature in Synapse Database: A Game-changer in Data Management
2 February 2024
The powerful intelligence alert function of the Patsnap Synapse database makes it easy for you to complete various monitoring tasks.
Read →
U.S. Fast-tracks ENHERTU® Assessment for Advanced HER2-Positive Solid Cancer Patients
Latest Hotspot
3 min read
U.S. Fast-tracks ENHERTU® Assessment for Advanced HER2-Positive Solid Cancer Patients
2 February 2024
U.S. authorities expedite assessment of ENHERTU® for individuals suffering from advanced solid cancers with HER2-positive status.
Read →